TNGXHealthcare · BiotechnologyThe 13 Wall Street analysts covering Tango Therapeutics, Inc. hold a median 12-month price target of $40 — +47.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 57 of 100 as at 1 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Tango Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (98): The shares have been drifting up relative to others.
Accruals (22): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
The rank is the raw material. Whether the rules would actually own Tango Therapeutics, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on TNGX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +47.0% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 July 2026 | Mizuho | Maintains | Outperform | $36 → $40 |
| 15 July 2026 | JP Morgan | Initiates | Overweight | $46 |
| 29 June 2026 | Canaccord Genuity | Maintains | Buy | — |
| 29 June 2026 | Canaccord Genuity | Maintains | Buy | $42 → $46 |
| 26 June 2026 | Jefferies | Upgrade | Buy | $27 → $60 |
| 26 June 2026 | Jefferies | Upgrade | Buy | — |
| 11 June 2026 | Canaccord Genuity | Maintains | Buy | — |
| 9 June 2026 | Canaccord Genuity | Maintains | Buy | — |
| 9 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 June 2026 | Leerink Partners | Maintains | Outperform | — |
| 15 May 2026 | Mizuho | Maintains | Outperform | — |
| 15 May 2026 | Piper Sandler | Downgrade | Neutral | — |
| 14 May 2026 | Jefferies | Downgrade | Hold | — |
| 14 May 2026 | Leerink Partners | Maintains | Outperform | — |
| 14 May 2026 | Wedbush | Maintains | Outperform | — |
| 27 Apr 2026 | Stifel | Maintains | Buy | — |
| 2 Apr 2026 | Canaccord Genuity | Initiates | Buy | — |
| 11 Mar 2026 | Mizuho | Maintains | Outperform | — |
| 9 Mar 2026 | Stifel | Maintains | Buy | — |
| 6 Mar 2026 | Guggenheim | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 97% of US stocks
Cheaper than 4% of US stocks
Cheaper than 10% of US stocks
Cheaper than 91% of US stocks
Higher than 1% of US stocks
Higher than 11% of US stocks
Higher than 2% of US stocks
Higher than 24% of US stocks
Higher than 19% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TNGX appears on the weeks it earns a place.
Zacks Investment Research reports that medical sector earnings are off to a strong start, and identifies four biotech companies positioned to potentially beat estimates in their upcoming quarterly results.
Why it matters — For TNGX watchers, the report signals a broadly favorable earnings environment for biotech companies in the medical sector heading into Q2 reporting season.
The 13 Wall Street analysts covering Tango Therapeutics, Inc. have a median 12-month price target of $40, with estimates ranging from $24 to $69. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Tango Therapeutics, Inc., 12 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tango Therapeutics, Inc. 57 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Tango Therapeutics, Inc. ranks 57 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +47.0% from the last close, and Ticker Nerd's factor model ranks Tango Therapeutics, Inc. 57 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Tango Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TNGX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $24 to $69 over the next 12 months.
Tango Therapeutics, Inc. returned +316.7% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Tango Therapeutics Inc. is a biotechnology company focused on discovering and developing precision oncology therapies.
The most recent item we track (Zacks Investment Research, 3 Aug 2026): "4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates". Zacks Investment Research reports that medical sector earnings are off to a strong start, and identifies four biotech companies positioned to potentially beat estimates in their upcoming quarterly results.
Tango Therapeutics Inc. is a biotechnology company focused on discovering and developing precision oncology therapies. The company applies synthetic lethality and target discovery approaches to identify cancer dependencies that can be addressed with medicines designed for specific tumor types. Its current pipeline centers on programs in oncology, including PRMT5 inhibitor candidates aimed at cancers such as pancreatic, lung, and brain tumors, along with research efforts tied to tumor suppressor gene loss and other genetically defined patient populations. Tango Therapeutics Inc. operates in the clinical-stage drug development segment, where its work contributes to the broader precision medicine market by advancing targeted approaches intended to improve cancer treatment specificity. The company is headquartered in Boston, Massachusetts, and is positioned within the life sciences sector as a developer of innovative therapeutic candidates for patients with high unmet medical need.
CEO Dr. Malte Peters M.D. · 137 employees · United States · https://www.tangotx.com